Imaging tumor phenotype: 1 Plus 1 is more than 2

Journal of Nuclear Medicine

Volumn 50, Issue 10, 2009, Pages 1567-1569

  Mankoff, David A ^a,c   Dehdashti, Farrokh ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Seattle Cancer Care Alliance ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE FREE INTERVAL; DRUG UPTAKE; ENDOCRINE GLAND; ENDOMETRIUM CANCER; GLUCOSE METABOLISM; HORMONAL THERAPY; HUMAN; METASTASIS; MOLECULAR IMAGING; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; THYROID CANCER; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR;

DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; PHENOTYPE;

EID: 70349650216     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.061044     Document Type: Review

References (25)

1. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol. 2006;2:689-700. (Pubitemid 44764211)
2. Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem. 2008;54:1770-1779.
3. Come SE, Buzdar AU, Ingle JN, et al. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008;112(3 suppl):673-678.
4. Kirby J, Heath PR, Shaw PJ, Hamdy FC. Gene expression assays. AdvClinChem. 2007;44:247-292.
5. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826. (Pubitemid 40051905)
6. Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? Eur J Cancer. 2008;44:2781-2790.
7. Tuttle RM, Leboeuf R, Shaha AR. Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol. 2008;97:712-716. (Pubitemid 351812974)
8. Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J Nucl Med. 2008;49(suppl 2):149S-163S.
9. 18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin EndocrinolMetab. 2006;91:498-505.
10. Krohn KA, O'Sullivan F, Crowley J, et al. Challenges in clinical studies with multiple imaging probes. Nucl Med Biol. 2007;34:879-885. (Pubitemid 47503826)
11. Hoffman EJ, van der Stee M, Ricci AR, Phelps ME. Prospects for both precision and accuracy in positron emission tomography. Ann Neurol. 1984;15(suppl):S25-S34.
12. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500-509.
13. 18f]- fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;11:1169-1175.
14. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
15. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803. (Pubitemid 32538187)
16. 18F-FDG PET. J Nucl Med. 2009;50:1598-1604.
17. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
18. Greer BE, Koh WJ, Abu-Rustum N, et al. Uterine neoplasms: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7:498-531. (Pubitemid 44265472)
19. Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control. 2009;16:38-45.
20. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212-1221.
21. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-48. (Pubitemid 18221696)
22. 18F- fluoroestradiol. J Nucl Med. 2008;49:367-374.
23. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799.
24. Weinhouse S. Isozyme alterations, gene regulation and the neoplastic transformation. Adv Enzyme Regul. 1983;21:369-386.
25. Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995-1000. (Pubitemid 351304582)